We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Alternative Biomarkers Found for Head and Neck Cancers

By LabMedica International staff writers
Posted on 04 Oct 2012
Human papillomavirus is a cause of some head and neck cancers, including oropharyngeal cancer, and patients with this viral-associated disease tend to have a better clinical outcome.

Human papillomavirus (HPV) DNA positivity alone, particularly when assessed using polymerase chain reaction (PCR) methods, is a poor biomarker for HPV-driven head and neck cancers, and alternative potential markers are needed.

Scientists at the German Cancer Research Center (Heidelberg, Germany) analyzed 199 oropharyngeal squamous cell carcinoma specimens for HPV DNA, viral load, ribonucleic acid (RNA) expression patterns seen in cervical carcinomas and the HPV-targeted tumor suppressor protein p16. Their results indicate that the cervical cancer RNA expression pattern and viral load were associated with the lowest risk for death from oropharyngeal cancer. In contrast, a weaker association was found for samples that were HPV DNA-positive or that expressed the protein p16, which is associated with tumor suppression.

In a separate study, the investigators evaluated several biomarkers individually and in combination for overall survival among head and neck cancers including PCR-based and serological HPV DNA testing, and p16 immunohistochemistry. They found that the expression of two oncoproteins, E6 and E7, was associated with improved survival in oropharyngeal disease. In addition, HPV DNA positivity or p16 expression combined with E6 and E7 expression were also associated with enhanced survival. However, neither HPV DNA positivity nor expression of p16 alone yielded a similar result.

Dana Holzinger, PhD, the senior author of the study said, "Once standardized assays for these markers, applicable in routine clinical laboratories, are established, they will allow precise identification of patients with oropharyngeal cancer with or without HPV-driven cancers and, thus, will influence prognosis and potentially treatment decisions." The studies were published on September 18, 2012, in the journal Cancer Research.

Related Links:

German Cancer Research Center




New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay

Latest Molecular Diagnostics News

DNA Methylation Signatures of Aging Could Help Assess Mortality Risk
04 Oct 2012  |   Molecular Diagnostics

Molecular Diagnostics System Provides Lab-Quality Results at POC
04 Oct 2012  |   Molecular Diagnostics

Cellular Signature Identifies Patients with Treatment Resistant Prostate Tumors
04 Oct 2012  |   Molecular Diagnostics



PURITAN MEDICAL